扩展二甲双胍中毒管理证据以支持决策
本文综述二甲双胍相关乳酸酸中毒的体外治疗证据。体外治疗中毒工作组2015年基于证据的共识推荐列出了临床和生化指征。后续回顾性研究显示,未达到工作组启动体外治疗标准的患者生存率为100%,达到标准者生存率约75%,其中仅66%接受了体外治疗,该治疗似乎未影响生存;另两项回顾性研究也未发现体外治疗改善生存,但接受体外治疗者病情更重。一项连续性肾脏替代治疗系统评价显示总体生存率高于工作组文献,作者据此提出间歇性血液透析可能并非二甲双胍中毒的首选治疗。作者认为目前仍应遵循工作组标准,尽量使用间歇性血液透析,证据多为回顾性研究,需前瞻性研究。
要点
- 未达到体外治疗中毒工作组启动体外治疗标准的患者生存率为100%,达到标准者生存率约75%。
- 达到工作组标准的患者中仅66%接受了体外治疗,该治疗似乎未影响生存。
- 另两项回顾性研究亦未发现体外治疗改善二甲双胍相关乳酸酸中毒患者的生存,但接受体外治疗者病情更重。
- 一项连续性肾脏替代治疗的系统评价显示总体生存率高于工作组文献所报告,作者据此提出间歇性血液透析可能并非二甲双胍中毒的首选治疗。
- 作者认为目前仍应遵循体外治疗中毒工作组标准,尽量使用间歇性血液透析,尤其重症中毒;病情较轻或间歇性血液透析不可及时可试用连续模式并密切观察恶化。
适用人群与场景
- 二甲双胍相关乳酸酸中毒患者,常在重症监护病房接受容量复苏等支持治疗,并考虑体外治疗以纠正代谢性酸中毒和清除二甲双胍及乳酸。
诊断标准与关键阈值
- 体外治疗中毒工作组2015年基于证据的共识推荐列出了临床和生化指征,并概述了每项推荐的依据和证据。
处置流程与药物剂量
- 作者认为目前仍应遵循体外治疗中毒工作组的指征,因为尚未有令人信服的理由改变这些标准。
- 在可能的情况下使用间歇性血液透析,尤其是严重中毒病例。
- 对于病情较轻或间歇性血液透析不易获得时,可试用连续模式并密切观察病情恶化。
研究设计与关键结果
- 一项回顾性研究显示,未达到体外治疗中毒工作组启动体外治疗标准的患者生存率为100%;达到标准者生存率约75%,其中仅66%接受了体外治疗,该治疗似乎未影响生存。
- 另两项回顾性研究显示,体外治疗未改善二甲双胍相关乳酸酸中毒患者的生存,但接受体外治疗者病情更重,可能支持该干预的获益。
- 一项接受连续性肾脏替代治疗患者的系统评价显示总体生存率高于体外治疗中毒工作组文献中的总体生存率,作者据此提出间歇性血液透析可能并非二甲双胍中毒的首选治疗。
- 仔细分析工作组数据发现,自20世纪70年代首次报告以来,生存率每十年均有改善。
- 有多篇报告显示标准连续性肾脏替代治疗未能改善的持续性二甲双胍相关乳酸酸中毒,促使增加体外治疗剂量。
证据类型、等级与局限
- 证据类型:综述,汇总回顾性研究、系统评价及体外治疗中毒工作组2015年基于证据的共识推荐。
- 支持上述观察的数据主要来自回顾性研究,存在固有偏倚,因此需要前瞻性研究。
对床旁实践的改变
- 作者认为目前仍应遵循体外治疗中毒工作组的指征,因为尚未有令人信服的理由改变这些标准。
- 作者建议在可能的情况下使用间歇性血液透析,尤其是严重中毒病例。
- 作者认为对于病情较轻或间歇性血液透析不易获得时,可试用连续模式并密切观察病情恶化。
指南或共识出处
- 体外治疗中毒工作组2015年发表的关于二甲双胍中毒体外治疗使用的基于证据的共识推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Metformin-associated lactic acidosis is a well-described and commonly encountered condition associated with significant morbidity and mortality. Patients with metformin-associated lactic acidosis are frequently managed in the intensive care unit with supportive care, including volume resuscitation and consideration of an extracorporeal treatment to correct metabolic acidemia and remove metformin and lactate.
EXTRACORPOREAL TREATMENTS IN POISONING WORKGROUP: The Extracorporeal Treatments in Poisoning Workgroup published evidence-based consensus recommendations in 2015 regarding the use of extracorporeal treatment in metformin toxicity. These recommendations list both clinical and biochemical indications, and they outline the rationale and evidence supporting each recommendation.
NEW RESEARCH SINCE RECOMMENDATIONS WERE PUBLISHED: Subsequent publications have provided new information regarding metformin-associated lactic acidosis and its treatment. A retrospective study showed that patients who did not meet the Extracorporeal Treatments in Poisoning Workgroup criteria for initiation of an extracorporeal treatment had a 100% survival. In patients who met the criteria, survival was approximately 75%; only 66% of these patients received an extracorporeal treatment, and this treatment did not appear to impact survival. Two other retrospective studies in patients diagnosed with metformin-associated lactic acidosis noted that extracorporeal treatments did not improve survival. However, those who received an extracorporeal treatment were more severely ill, potentially supporting a benefit from this intervention. A systematic review of patients receiving continuous kidney replacement therapy identified an overall survival that was higher than the overall survival in patients included in the Workgroup publication. This led the authors to suggest that intermittent hemodialysis may not be the preferred treatment for metformin toxicity. However, a closer look at the Workgroup data identified improved survival with each decade since the initial reports in the 1970s. Furthermore, there are multiple reports of persistent metformin-associated lactic acidosis that did not improve with standard continuous kidney replacement therapy, prompting an increase in the dosage of the extracorporeal treatment. The data supporting these observations are largely derived from retrospective studies, which have inherent biases, so prospective studies are required.
PRESCRIBING EXTRACORPOREAL TREATMENTS FOR PATIENTS WITH METFORMIN POISONING: Case-based decision-making is always necessary, but in general, we continue to follow the Extracorporeal Treatments in Poisoning Workgroup criteria because a convincing reason for changing these has not yet been presented. This includes the use of intermittent hemodialysis where possible, particularly in cases of severe poisoning. For patients with less severe poisoning or when intermittent hemodialysis is not readily available, it is reasonable to trial continuous modalities with careful observation for deterioration.
参考来源
- Roberts DM, Ghannoum M. Expanding the evidence for managing metformin poisoning to support decision-making. Clin Toxicol (Phila). 2023. PMID: 37129225. doi:10.1080/15563650.2023.2196372
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。